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Abstract
Excess glutamate release and associated neurotoxicity contributes to cell death after spinal cord injury (SCI). Indeed, delayed
administration of glutamate receptor antagonists after SCI in rodents improves tissue sparing and functional recovery.
Despite their therapeutic potential, most glutamate receptor antagonists have detrimental side effects and have largely
failed clinical trials. Topiramate is an AMPA-specific, glutamate receptor antagonists that is FDA-approved to treat CNS
disorders. In the current study we tested whether topiramate treatment is neuroprotective after cervical contusion injury in
rats. We report that topiramate, delivered 15-minutes after SCI, increases tissue sparing and preserves oligodendrocytes and
neurons when compared to vehicle treatment. In addition, topiramate is more effective than the AMPA-receptor antagonist,
NBQX. To the best of our knowledge, this is the first report documenting a neuroprotective effect of topiramate treatment
after spinal cord injury.
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Introduction
Tissue loss after spinal cord injury (SCI) is the result of primary
physical damage and secondary apoptotic and necrotic cell death.
Cytokines, neurotransmitters, and blood products released by the
initial physical trauma create a toxic environment for neurons and
oligodendrocytes. For example, levels of the pro-inflammatory
cytokine, TNF-a, increase acutely after injury. Neurons, in
response to high levels of TNF-a, traffic glutamate receptors to
their cell membrane thereby becoming more sensitive to
excitotoxic cell death [1]. TNF-a also increases the susceptibility
of oligodendrocytes to excitoxic cells death [2]. Levels of pro-
inflammatory cytokines and glutamate increase after injury
coincident with neuron and oligodendrocyte loss [3].
Although extracellular levels of glutamate reach toxic levels
shortly after SCI [4,5], delayed administration of drugs that
directly antagonize glutamate receptors reduces cell loss and
improves motor recovery [6]. Even when delayed by 4 hrs after
SCI, the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA)/kainic acid (KA) glutamate receptor antagonist
NBQX improves functional recovery and tissue sparing [7].
Unfortunately, this drug, and many other glutamate receptor
antagonists, have detrimental side effects and have largely failed
clinical trials [8–10].
In an effort to find clinically feasible approaches for limiting
excitotoxic cell death after SCI we tested the neuroprotective
potential of topiramate treatment in a model of cervical SCI.
Topiramate is a potent AMPA receptor antagonist FDA approved
for clinical treatment of epileptic seizures and migraines.
Topiramate treatment is also neuroprotective and rescues
oligodendrocytes in models of traumatic brain injury, stroke,
epilepsy, and Periventricular leukomalacia [11–14]. We report
that topiramate delivery 15 minutes after SCI increases tissue
sparing, preserves oligodendrocytes, and saves motor neurons
compared to vehicle and NBQX controls. To the best of our
knowledge this is the first report examining the neuroprotective
potential of topiramate in a SCI model.
Methods
Animals and Surgery
Fifty-two female, Long-Evans rats (Simonsen Laboratories, CA,
USA) 75–85 days old and weighing an average of 236+/22 grams
were anesthetized with sodium pentobarbital (Nembutal, Abbott
Laboratories, IL, USA; 45–60 mg/kg) and received prophylactic
antibiotics (cefazolin; Ancef, Novation, LCC, TX, USA; 25 mg/
kg). Body temperatures were monitored throughout the surgical
procedure and maintained at 37+/22uC. Cervical contusion
injuries were performed as described in detail previously [15].
Briefly, a single level laminectomy was performed at C5 and right
unilateral SCI produced using the MASCIS/NYU injury device
[16,17]. Two severities of injury were produced by dropping a 10-
gram weight from a height of either 12.5 mm or 6.25 mm. The
12.5 mm weight drop damages .80% of the tissue ispilateral to
the injury and is hereafter referred to as a severe injury [15]. The
6.25 mm weight drop damages ,50% of the hemicord and is
hereafter referred to as a moderate injury [15].
Drug administration
The dura was opened immediately after SCI and the animal
was placed in a stereotaxic frame. Twelve minutes and thirty
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(diameter=180 um; World Precision Instruments, FL, USA) was
lowered to a depth of 2.0 mm into the center of the contused area
of the spinal cord using a micromanipulator. The spinal cord was
allowed to acclimate to the syringe for 2.5 minutes before the
solution was delivered. Starting 15 minutes after the contusion,
3 ml of one of three solutions was delivered over 10 minutes: 1)
8.9–9.3 mM NBQX (NBQX disodium salt; Tocris, MO, USA)
dissolved in water; 2) 10 mM topiramate (Sigma, MO, USA)
dissolved in water; or 3) vehicle (sterile water). The syringe was left
in place for 5 minutes after the injection then withdrawn.
Withdrawal was delayed to prevent drug solutions from leaking
out the needle tract. After drug delivery and syringe withdrawal,
wounds were closed in layers and animals placed in 37uC
incubators overnight with food and water freely available. The
following day, animals were returned to their cages with ad libitum
access to food and water. Animals were then monitored daily to
ensure good health. Four animals died during, or shortly after,
surgery. These animals were replaced to yield final groups sizes of
n=8.
Histological Preparation
48-hours after contusion injury animals were anesthetized
(ketamine-xylazine) and transcardially perfused 0.5 ml of 2%
lidocaine HCL, 0.1 ml of heparin, 300–500 ml of 0.9% NaCl and
500–1000 ml of 4% paraformaldehyde. Spinal cords were
removed and post-fixed for 24 hrs then cryoprotected in 30%
sucrose. A 10-mm block of spinal cord tissue, centered on the
injection site, was cut into 6 serial sets of 20-um thick frontal
sections using a cryostat and mounted on glass slides. To quantify
tissue sparing, sections were stained with cresyl violet, for cell
bodies, and Luxol fast blue, for myelin. For immunohistochemical
labeling, sections were washed with PBS, permeabilized with 0.3%
triton in PBS, and then incubated overnight with primary
antibodies prepared in blocking solution. Neuron-Specific Nuclear
Protein (NeuN; 1:200 dilution; Chemicon, Temecula, CA, USA) is
specific to neurons and in the spinal cord only labels cell in the
gray matter [18,19]. CC1 antibody (1:500; Oncogene Research
Products, Cambridge, MA) was used to identify oligodendrocytes.
Primary antibodies were visualized through application of a
secondary antibody for 1 hour at room temperature (Alexa-Fluor
488; Goat anti-Mouse IgG; 1:250; Molecular Probes, Eugene,
OR, USA). Sections were then rinsed with PBS and cover-slipped
with Vectashield with DAPI (nuclear counterstain) hard-set
mounting media (Vector’s Laboratory Inc., Burlinghame, LA,
USA).
Anatomical Analysis
The center of the lesion (lesion epicenter) was identified as the
area with maximal tissue damage. Tissue sparing was assessed at
1 mm-intervals centered on the lesion epicenter. Camera lucida
drawings were made to quantify spared tissue and lesion areas.
Lesion was defined as areas in the gray matter devoid of neuronal
cells, areas absent of Luxol fast blue staining in the white matter,
and/or areas of gliosis. The proportion of spared tissue area
relative to total cross sectional area was calculated for each tissue
section and averaged across 7 mm centered on the lesion
epicenter.
The density of CC1 immunoreactivity in the dorsal column
(DC) and ventral column (VC) white matter and the number of
NeuN+ neurons were quantified through threshold-based mea-
sures of digital images with the MetaMorph Offline Meta Imaging
Series version 6.3r software (Universal Imagining Systems, PA,
USA). Images were captured for each hemi-cord at 1 mm intervals
centered on the lesion epicenter using an Axioplan 2 imaging
microscope (Zeiss, Oberkochen, Germany). Manual threshold
levels were set to include positively stained cells while excluding
background staining for each image. DC oligodendrocyte
measurements were made using a standard size box aligned with
medial edge of the dorsal horn of the gray matter and the dorsal
edge of the spinal cord. VC oligodendrocyte measurements were
made using a standard size box aligned with the ventral median
sulcus and the ventral edge of the spinal cord. The proportional
area of CC1+ immunoreactivity was recorded for each area.
Neuron counts were estimated from the entire gray matter
containing cells stained positively with NeuN. The length of the
major axis of each cell was calculated using the integrated
morphometry analysis function in metamorph in order to count
small (10–15 mm in length), medium (15–30 mm in length), and
large (over 30 mm in length) neurons. This definition was adapted
from [20]. In that study, cresyl violet or hematoxylin-floxine
labeled cells were counted in an automated fashion and were
defined as small (5–10 mm), medium (10–15 mm), and large
(.15 mm) according to the major axis. NeuN has a tendency to
label dendrites and cell bodies along with the nucleus of the cell
[19], so a larger size criteria was used to adapt this technique.
Behavioral Analysis
Forelimb grooming function was assessed with a six-point
scoring system as previously described [15]. Briefly, grooming
activity was scored depending upon the area of the head contacted
by the animal’s forelimb: 0- no contact to any part of the face or
head; 1-the underside of the chin and/or the mouth area; 2-the
area between the nose and the eyes; 3- the eyes and/or the area up
to the front of the ears; 4-the front but not the back of the ears; 5-
area of the head behind the ears. Locomotor recovery was scored
during open field observation for 4 minutes. Hindlimb function
was assessed using the 13-point sub-scoring system for the Basso,
Beattie, Bresnahan test of locomotor recovery [21,22]. The sub-
score system assigns values to each hindlimb for toe drags, paw
position, tail position, and trunk instability (Table S1).
Statistics
Open field and grooming data were analyzed using ANOVA.
NeuN cell counts and all area measures were compared using a
two-within, one-between mixed ANOVA. Within subject factors
were side (ipsilateral or contralateral to the injury) and distance
from the injection site; the between subject factor was treatment
condition. Significant interactions were accounted for by exam-
ining either side (contralateral or ipsilateral) or distance (rostral or
caudal) separately. Based on these interactions, neuron counts and
sparing measures are reported only for the side ipsilateral to injury.
ANOVA’s were followed by Dunnett’s or Tukey’s test for multiple
comparisons. Independent samples t tests were also used to
compare two groups separately. Graphpad Grubb’s test (extreme
studentized deviate method http://www.graphpad.com/quick
calcs/Grubbs1.cfm;) was used to remove statistical outliers. All
p-values below 0.05 were considered significant. Unless noted
otherwise, all data represent the mean 6 SEM. All analyses were
performed using SPSS 14 for Windows (SPSS Inc., Chicago, IL,
USA) or GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla,
CA). Figures were prepared using Adobe Photoshop CS (Adobe
Systems Inc., San Jose, CA) and GraphPad Prism 5.0.
Results
There were no differences among vehicle, NBQX, or
topiramate treated groups for any anatomical or functional
Topiramate Treatment for Spinal Cord Injury
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contusion injury (p.0.50 for ANOVAs of all outcome measures;
data not shown). All the results below refer to treatment after
severe (12.5 mm) contusion injury.
Tissue Sparing
Swelling occurs in the acutely injured spinal cord and can
confound area based sparing measures [23]. To overcome this
confound we normalized spared tissue areas to spinal cord cross
sectional area. Animals receiving topiramate treatment 15 minutes
after severe injury had significantly more spared tissue compared
to vehicle treated controls (Fig. 1A–D; p,0.05). Sparing was
measured 48 hrs after injury and primarily occurred in the dorsal
medial and ventral medial white mater (Fig. 1A–C). NBQX-
treatment increased sparing compared to controls but the effect
was not statistically significant (p=0.07, Fig. 1D).
Oligodendrocyte Survival
We detected increased oligodendrocyte preservation in topir-
amate treated animals compared to vehicle or NBQX-treated
controls (Fig. 1E–H). Topiramate treatment significantly improved
oligodendrocyte sparing after severe SCI in the dorsal column
white matter (p,0.05 vs. NBQX or vehicle; Fig. 1E) but not in the
ventral white matter (p=0.23; data not shown). No significant
differences were detected between NBQX and vehicle control.
Neuronal Survival
Neurons are lost within the first 24 hrs following contusion
injury [24]. In order to assess treatment-induced neuronal survival
we counted the number of NeuN-positive cells 48 hrs after severe
contusion injury. Animals receiving topiramate treatment had
significantly more small and medium sized neurons compared to
vehicle or NBQX-treated controls (Figure 2). Neurons were spared
primarily in the dorsal horn and around the central canal of the
gray matter (Fig. 2A–F). We also detected more large-diameter
motoneurons sparing with topiramate treatment although the
effect was not statistically significantly (ANOVA, p=0.051;
Fig. 2H). NBQX treatment did not improve motor neuron
sparing compared to vehicle controls (Fig. 2).
Behavioral Recovery
We assessed motor recovery by testing grooming and locomotor
function 2 days after severe SCI. Grooming scores for animals
treated with topiramate (1.3+/20.3) were better then vehicle
(1.0+/20.3) or NBQX-treated (0.3+/20.2), however significant
effects were only detected for topiramate vs. NBQX-treated
animals (p,0.05) (Fig. S1). There were no significant locomotor
differences among treatment groups (Fig. S1). Animals had
frequent to consistent weight supported stepping (.50% of the
time) with some abnormal paw rotation, trunk instability, and tail
drags.
Discussion
Following the primary insult of spinal cord injury, toxic amounts
of glutamate are released and large numbers of neurons and
oligodendrocytes are lost through excitotoxic and other secondary
mechanisms [3,4]. We show that the AMPA receptor antagonist,
Figure 1. Tissue sparing and oligodendrocyte labeling 48 hrs after severe spinal cord injury. (A–D) Topiramate treated animals had more
spared tissue compared to vehicle controls. (A–C) Reprehensive camera Lucida drawing of lesion epicenters from different treatment conditions
(lesion area in gray). Notice the increased tissue sparing following topiramate (TPM) and NBQX treatment in the dorsal horn and ventromedial white
matter compared to vehicle treated. D) Topiramate and NBQX-treatment increased the average proportional area of tissue spared. Area was
quantified over 6 mm centered on the lesion epicenter. E–G) Representative examples of CC1 immunoreactivity in the dorsal columns caudal to the
lesion epicenter. Arrows identify areas with no CC1+ cells in vehicle and NBQX conditions (E–F), while arrowheads (in G) identify the same areas with
CC1+ cells in the topiramate condition. More CC1 labeling is also evident in the dorsal horn (DH) for topiramate treated animals. H) The density of CC1
immunoreactivity was significant increased with topiramate treatment. *p,0.05; p=0.07 for NBQX vs. vehicle.
#p,0.05 for topiramate vs. vehicle or
NBQX for average CC1 density caudal to the lesion epicenter.
doi:10.1371/journal.pone.0033519.g001
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minutes after SCI. Significantly more neurons and oligodendro-
cytes are spared in animals treated with topiramate after cervical
spinal cord contusion injury compared to vehicle control.
Topiramate is more effective than the well-documented neuro-
protective AMPA receptor antagonist, NBQX. Unlike other
glutamate receptor antagonists which have failed clinical trials
due to undesired side effects [8,10]; topiramate is clinically
available for treatment of migraines and epileptic seizures and
tolerated by individuals with SCI [25,26]. To the best of the
authors’ knowledge, the current study is the first demonstration of
topiramate’s neuroprotective potential as a therapy for spinal cord
injury.
A variety of factors contribute to neurotoxicity after SCI making
it likely that combinatory approaches or multi-mechanistic drugs
are needed for clinical efficacy. Mechanical induced depolariza-




channels and release excitatory neurotransmitters. Ultimately this
increased activation causes intracellular Ca
2+ accumulation and
induces a cascade of molecular events resulting in cell death [6,27].
While drugs with single mechanisms of action can be protective
after injury, multi-mechanistic drugs may more effectively reduce
excitoxic cell death. NBQX can improve mitochondrial function
and reduced oxidative events after SCI [28]. Indeed, in agreement
with of previous reports, we detected increased tissue sparing with
NBQX-treatment vs. control (Fig. 1) [29]. Similar to other
published reports, however, NBQX was not sufficient to reduce
neuron loss in the current study (Fig. 2) [30].
The multi-mechanistic properties of topiramate make it a
promising therapy for treating SCI. Topiramate is a broad
spectrum anticonvulsant that in addition to antagonizing gluta-
mate receptors, enhances the effects of the inhibitory neurotrans-
mitter GABA; reduces the activity of voltage gated sodium and
calcium channels; and blocks calcium influx into cells [26]. Since
treatment with either GABA agonists or sodium channel blockers
confers neuroprotection in models of SCI [31,32], it is likely that
these other mechanisms of action contribute to the increased
neuroprotection detected with topiramate compared to NBQX.
In the current study we provide proof of principle evidence that
topiramate can be neuroprotective when delivered after SCI and
although we injected topiramate directly into the spinal cord, the
dose used has clinical significance. We delivered a total of
30 nmols of topiramate into the cord. In rats, brain concentrations
of topiramate reach roughly 1/1000 the concentration delivered
orally [33]. The equivalent oral dose in the current study would be
40–50 mg/kg. Doses in this range lead to tissue sparing and
behavioral improvements following damage to the CNS [11–13];
are below the value of ED50 causing motor impairments in rats
[34]; and would likely be tolerated by humans [26].
Interestingly, topiramate was only effective when delivered after
severe, but not moderate SCI. This is likely due to differences in
secondary injury progression and overall damage between the two
Figure 2. Topiramate treatment significantly increased NeuN+ neuron sparing 48-hrs after severe spinal cord injury. A–F)
Representative examples of NeuN labeling ipsilateral to the side of injury 1 mm-caudal to lesion epicenter. Pictures are from around the central canal
(A,C,E) and dorsal horn (B,D,F). Notice the increased number of neurons in the topiramate treated group. G) The number of small sized neurons
remaining 48 hrs after injury by group. Graphs were similar for medium and large sized neurons. H) More small, medium, and large neurons were
spared caudal to the lesion epicenter following topiramate treatment (ANOVA for large diameter neurons, p=0.051).
#,&p,0.05 for topiramate vs.
vehicle;
#p=0.052 and
&0.057 for topiramate vs. NBQX. *There were significant differences among groups as a function of distance from the lesion
epicenter; therefore only caudal neuron numbers were considered in (H) (p,0.05 for distance x group interaction two-way ANOVA).
doi:10.1371/journal.pone.0033519.g002
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injury indicate that microvasculature remains intact after milder
injury [35]. Therefore less hemorrhage, a predictor of secondary
injury and lesion progression [36], occurs with milder injury.
Indeed, following cervical contusion injury, progressive gray
matter loss is detectable only after severe, but not moderate or
mild injury [37]. In addition, acute white matter loss, within 3 dpi,
only occurs after severe injury [37]. Collectively, these finding
predict the results of the current study; acute treatments aimed at
limiting secondary injury progression after cervical injury, i.e.
topiramate, may be more effective after severe injury.
Topiramate treatment improved oligodendrocyte sparing in the
dorsal columns, but not ventral white matter. Topiramate was
microinjected through the dorsal surface of the spinal cord. This
route of administration may have resulted in less drug penetration
into the ventral vs. dorsal spinal cord. Ventral column white
matter is also further from impact site and myelinated axon loss is
less pronounced here than in the dorsal columns after cervical
injury [37]. Lack of penetration, both due to route of
administration and maintained tissue integrity in the ventral
columns, may therefore contribute to the region specific
oligodendrocyte sparing following topiramate treatment.
Since topiramate treatment increased neuron sparing after SCI,
it may be a useful drug to treat individuals with cervical injuries. In
order for successful translation from basic science to clinical
application, therapies should be tested in contusion models of
injury and mimic treatment approaches applicable to humans
[38]. The more accurately these models reproduce the human
condition, the greater the potential for successful translation. We
tested topiramate treatment in a model of cervical SCI. The
cervical spinal cord is the most common spinal level of injury in
humans and treatments that improve hand function are the
number one priority of these individuals [39]. Treatments that
spare motor neurons may address this priority. Indeed, neuronal
sparing that reduces motor deficits by even one spinal level
dramatically improves the quality of life for the cervically injured
[40]. More work is needed to determine the therapeutic window of
topiramate treatment and if treatment can increase long-term
motor recovery. Nonetheless, by determining that topiramate is
protective and spares neurons after severe, but not moderate
injury, we now have insight into which injury populations may be
suitable therapeutic targets.
We report that acute topiramate treatment is protective against
secondary damage caused by SCI. In addition, repeated
administration is tolerated in spinal cord injured patients, reduces
injury induced pain in humans, and increases neurite outgrowth
after nerve injury [25,41]. Further studies are in progress to extend
this potential therapy to preclinical treatment paradigms that are
more relevant to clinical application, including systemic routes of
administration and initiation of treatment at longer post-injury
time points.
Supporting Information
Figure S1 Locomotor and grooming function 48 hrs
after severe SCI. (A) There were no significant effects of
treatment on locomotor function. (B) Animals treated with NBQX
had significant worse grooming function with the limb ipsilateral
to injury compared to topiramate treated (*p,0.05). Neither
NBQX nor topiramate treated animals differed significantly from
vehicle. Scores for the limb contralateral to the injury did not differ
from uninjured controls (data not shown).
(TIF)
Tables S1 Open field subscore catagories. IC=initial contact,
LO= lift off. Toe clearance and paw position are scored for each
hindpaw individually then summed.
(DOC)
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